Retro Biosciences, backed by OpenAI CEO Sam Altman, is launching a clinical trial for a novel drug aimed at reversing Alzheimer’s disease through cellular reprogramming techniques. The startup, which recently secured $1 billion in funding, aims to extend human healthspan and tackle broader cognitive decline as it navigates the complexities of regulatory approval and ethical considerations in longevity research.